Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research
May 09, 2024 08:00 ET
|
Optimi Health Corp.
Export Permit granted: Optimi's Shipment of MDMA active pharmaceutical ingredient (API) to Israel marks the Company’s first international export
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
April 23, 2024 08:18 ET
|
Optimi Health Corp.
Optimi Health announces innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre.
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
April 15, 2024 08:00 ET
|
Optimi Health Corp.
Optimi announces completion of three batches of its MDMA API manufactured from raw materials under the Company’s Precursor Licence.
Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract
April 02, 2024 07:30 ET
|
Optimi Health Corp.
Optimi receives Certificate Of Analysis for GMP Natural Psilocybin Extract. Company has also completed the in-house encapsulation of 5mg & 10mg psilocybin.
Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference
March 28, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Health secures Presenting Sponsorship at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston, MA.
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University
March 26, 2024 07:30 ET
|
Optimi Health Corp.
Supply agreement marks Optimi’s first international shipment of research-grade active pharmaceutical ingredient (API) MDMA to Israel
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
February 12, 2024 07:00 ET
|
Optimi Health Corp.
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
Optimi Announces Non-Brokered Private Placement
February 08, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Announces Non-Brokered Private Placement
Optimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And Practitioners
February 06, 2024 07:30 ET
|
Optimi Health Corp.
Highlights: Optimi Chief Science and Quality Assurance experts to provide in-depth access into the Company’s safety and quality standards.Optimi experts will address critical inquiries which still...
Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
January 19, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Health granted amendment to its Health Canada Controlled Drugs and Substances Licence.